Symbols

NSPR

InspireMD·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Revenue Beats Expectation

EPS Beats Expectation

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NSPR

Inspiremd, Inc.

A developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke

Industry

Healthcare Equipment and Supplies

Established Date

02/29/2008

Listing Date

05/24/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

127

Fiscal Year Ends

12-31

Website

www.inspiremd.com

Security Type

Common stock

Office address

6303 Waterford District Drive, Suite 215, Miami, Florida 33126

Business

Introduction

InspireMD, Inc., was incorporated in Delaware on February 29, 2008. The company is a medical device company focused on the development and commercialization of products for the treatment of carotid artery disease, with CGuard carotid stent technology at its core. Its product portfolio includes CGuard EPS and CGuard Prime, designed to provide embolic protection during stent implantation, of which CGuard Prime has been approved for sale in the US market.

Company Financials

EPS

NSPR has released its 2025 Q4 earnings. EPS was reported at -0.14, versus the expected -0.19, beating expectations. The chart below visualizes how NSPR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NSPR has released its 2025 Q4 earnings report, with revenue of 3.15M, reflecting a YoY change of 61.57%, and net profit of -11.76M, showing a YoY change of -28.20%. The Sankey diagram below clearly presents NSPR's revenue sources and cost distribution.